Drug eluting stents: Key market research findings
- Technological advancements and redesigning drug-eluting stents
- Increased usage of hybrid processes in CVDs
Technavio has added a new market research report on the drug eluting stent market in China, to its stent market. The drug eluting stent market in China is expected to grow at a CAGR of around 11% between 2015 and 2019, due to the high prevalence of cardiovascular diseases (CVDs), such as hypertension, stroke, myocardial infarction, and heart failure. Drug-eluting stents help the artery to remain open and smooth, and allows proper blood flow. These stents comprise a stent, polymer and drugs.
The new industry research report from Technavio discusses in detail the key drivers and trends responsible for growth, as well as the segments with the maximum growth potential.
“Vendors are increasingly focusing on the design of drug-eluting stents for better efficiency in treatment. Manufacturers are using biodegradable polymer in these stents as it improves the ability to keep the artery open, prevent re-clogging, and reduce stent thrombosis by 50%. For instance, JW Medical Systems’ “EXCEL II” is the latest biodegradable-polymer drug-eluting stents product. Biosensors’ BioMatrix Flex stent system is an anti-restenosis drug, with a biodegradable polylactic acid polymer abluminal coated on the highly flexible stent platform, says Imran Mushtaq, Lead Analyst, Healthcare,Technavio Research.
Growing popularity of hybrid procedures for the treatment of CVDs is elevating the need for drug eluting stents. Hybrid processes combine minimally invasive coronary artery bypass surgery with stenting. These procedures remove plaque from the blood vessels entirely, ensuring better recovery. Post-bypass surgery and angioplasty, drug-eluting stenting is used to minimise re-blockage of the artery. Both stenting and bypass surgery are performed simultaneously, which helps patients to save time and cost.
The leading vendors in the drug eluting stent market in China are MicroPort Scientific, Lepu Medical, Shandong JW Medical Systems, Abbott Vascular, and Medtronic. Competition in the market is expected to intensify with an increase in product extensions and technological innovations in drug eluting stents, which is facilitating vendors to expand their businesses in China.
A more detailed analysis is available in the Technavio report, Drug Eluting Stent Market in China – Industry Research Report 2015-2019.
We can customize reports by other regions and specific segments upon request.
Other Related Reports:
- Stent Grafts Market in China 2015-2019
- Global Carotid Stent Market 2015-2019
- PTCA Balloon Catheter Market in China 2015-2019
- Global Coronary Stents Market 2014-2018
- Global Drug-eluting Stent Market 2014-2018
Further Reading:
